Association of hypertension with mortality in patients hospitalised with COVID-19

Kunwardeep S. Bhatia, Hari P. Sritharan, Jonathan Ciofani, Justin Chia, Usaid K. Allahwala, Karina Chui, Daniel Nour, Sheran Vasanthakumar, Dhanvee Khandadai, Pavithra Jayadeva, Rohan Bhagwandeen, David Brieger, Christopher Choong, Anthony Delaney, Girish Dwivedi, Benjamin Harris, Graham Hillis, Bernard Hudson, George Javorski, Nigel JepsonLogan Kanagaratnam, George Kotsiou, Astin Lee, Sidney T. Lo, Andrew I. Macisaac, Brendan McQuillan, Isuru Ranasinghe, Antony Walton, James Weaver, William Wilson, Andy S.C. Yong, John Zhu, William Van Gaal, Leonard Kritharides, Clara K. Chow, Ravinay Bhindi

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)


Objective To assess whether hypertension is an independent risk factor for mortality among patients hospitalised with COVID-19, and to evaluate the impact of ACE inhibitor and angiotensin receptor blocker (ARB) use on mortality in patients with a background of hypertension. Method This observational cohort study included all index hospitalisations with laboratory-proven COVID-19 aged ≥18 years across 21 Australian hospitals. Patients with suspected, but not laboratory-proven COVID-19, were excluded. Registry data were analysed for in-hospital mortality in patients with comorbidities including hypertension, and baseline treatment with ACE inhibitors or ARBs. Results 546 consecutive patients (62.9±19.8 years old, 51.8% male) hospitalised with COVID-19 were enrolled. In the multivariable model, significant predictors of mortality were age (adjusted OR (aOR) 1.09, 95% CI 1.07 to 1.12, p<0.001), heart failure or cardiomyopathy (aOR 2.71, 95% CI 1.13 to 6.53, p=0.026), chronic kidney disease (aOR 2.33, 95% CI 1.02 to 5.32, p=0.044) and chronic obstructive pulmonary disease (aOR 2.27, 95% CI 1.06 to 4.85, p=0.035). Hypertension was the most prevalent comorbidity (49.5%) but was not independently associated with increased mortality (aOR 0.92, 95% CI 0.48 to 1.77, p=0.81). Among patients with hypertension, ACE inhibitor (aOR 1.37, 95% CI 0.61 to 3.08, p=0.61) and ARB (aOR 0.64, 95% CI 0.27 to 1.49, p=0.30) use was not associated with mortality. Conclusions In patients hospitalised with COVID-19, pre-existing hypertension was the most prevalent comorbidity but was not independently associated with mortality. Similarly, the baseline use of ACE inhibitors or ARBs had no independent association with in-hospital mortality.

Original languageEnglish
Article numbere001853
JournalOpen Heart
Issue number2
Publication statusPublished - 7 Dec 2021


Dive into the research topics of 'Association of hypertension with mortality in patients hospitalised with COVID-19'. Together they form a unique fingerprint.

Cite this